Trials / Completed
CompletedNCT00081601
Study of CEP-701 in Treatment of Prostate Cancer
An Open-Label Phase 2 Study of Oral CEP-701 in Patients With Asymptomatic Hormone-Refractory Cancer With Rising Prostate Specific Antigen
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 30 (planned)
- Sponsor
- Cephalon · Industry
- Sex
- Male
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to determine the proportion of patients with a serological prostate specific antigen (PSA) by day 85.
Detailed description
A serological PSA response is defined as a reduction from baseline PSA serum concentration of at least 50%, which is confirmed by a second PSA value 28 or more days later.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | CEP-701 |
Timeline
- Start date
- 2004-03-01
- Primary completion
- 2005-05-01
- Completion
- 2005-06-01
- First posted
- 2004-04-19
- Last updated
- 2012-08-24
Locations
1 site across 1 country: United States
Source: ClinicalTrials.gov record NCT00081601. Inclusion in this directory is not an endorsement.